Status:
RECRUITING
Wearable Enhanced Fitness Tracking for Metastatic Breast Cancer Patients Using Endocrine Treatment and Palbociclib
Lead Sponsor:
Beneficência Portuguesa de São Paulo
Conditions:
Breast Neoplasm Female
Quality of Life
Eligibility:
FEMALE
18+ years
Phase:
NA
Brief Summary
Combining a fitness tracker technology with real-time patient-reported outcome monitoring associated with interventions through a health care app is a novel strategy to evaluate metastatic breast canc...
Detailed Description
Measure the quality of life of patients with metastatic breast cancer treated with Palbociclib and endocrine therapy using the Functional Assessment of Cancer Therapy - Breast and EuroQol -5D - Europe...
Eligibility Criteria
Inclusion
- Female patients ≥ 18 years of age diagnosed with hormone receptor-positive/ human epidermal growth factor receptor 2- negative metastatic breast cancer undergoing treatment with Palbociclib combined with aromatase inhibitors (letrozole, exemestane or anastrozole) or fulvestrant as first-line therapy, or in treatment with Palbociclib and fulvestrant as second-line or posterior-line therapy in the metastatic setting; may be using ovarian suppression if the patient is premenopausal.
- The patient must be on treatment for at least three (3) months with Palbociclib and endocrine therapy.
- Evidence of a signed and dated informed consent document, physically or digitally, indicating that the research participant was informed about all relevant aspects of the study;
- The patient agrees not to participate in another study with drug intervention while on treatment.
- Have performance status according to the Eastern Cooperative Oncology Group
- Have access to a compatible smartphone and 3G or 4G internet connection
Exclusion
- Patients considered to be at poor medical risk due to uncontrolled serious medical disorder, non-malignant systemic disease, or active uncontrolled infection. Examples: uncontrolled ventricular arrhythmia, recent myocardial infarction (within 6 months), stroke, gastrointestinal bleeding, or any psychiatric disorder that precludes informed consent; between others.
- Patients who have a life expectancy of \< 3 months.
- Treatment with any product under investigation during the last 28 days;
- Another acute or chronic medical or psychiatric condition or severe laboratory abnormality that could increase the risk associated with participation in the study or that Page 10 de 21 Version 6.0 could interfere with the interpretation of the study results and, in the investigator's judgment, would make the research participant unsuitable for inclusion in the study. study.
- Illiterate patients or those with a low level of education that may prevent the correct use of the Wecancer application and/or the watch with monitoring of physical activity.
Key Trial Info
Start Date :
April 22 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2025
Estimated Enrollment :
68 Patients enrolled
Trial Details
Trial ID
NCT05277935
Start Date
April 22 2022
End Date
March 1 2025
Last Update
August 26 2024
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Oncoclínicas
Rio de Janeiro, Brazil
2
A Beneficência Portuguesa de São Paulo
São Paulo, Brazil
3
A.C.Camargo Cancer Center
São Paulo, Brazil
4
Centro Paulista de Oncologia
São Paulo, Brazil